$41.65
-0.70-1.65%
À la fermeture: -
$42.36
0.711.70%
Après les heures de négociation: 7:43 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Exelixis Inc a un objectif de cours consensuel de $43.79 basé sur les évaluations de 26 analystes. Le plus élevé est $60, publié par Stephens & Co. le juin 24, 2025. Le plus bas est $27, publié par BTIG le décembre 19, 2023. Les 3 évaluations d’analystes les plus récentes ont été publiées par UBS, TD Cowen et Morgan Stanley le novembre 6, 2025, novembre 5, 2025 et novembre 5, 2025, respectivement. Avec un objectif de cours moyen de $45.33 entre UBS, TD Cowen et Morgan Stanley, il existe une variation implicite de 7.02% upside pour Exelixis Inc selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
UBS
TD Cowen
Morgan Stanley
Barclays
HC Wainwright & Co.
1calculé à partir des notes des analystes
Notes d'analystes pour Exelixis
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | -5.57% | UBS | $35 → $40 | Maintains | Neutral | |||
11/05/2025 | 20.4% | TD Cowen | $44 → $51 | Maintains | Buy | |||
11/05/2025 | 6.23% | Morgan Stanley | $44 → $45 | Maintains | Overweight | |||
11/05/2025 | -3.21% | Barclays | $40 → $41 | Maintains | Equal-Weight | |||
11/05/2025 | 15.68% | HC Wainwright & Co. | $46 → $49 | Maintains | Buy | |||
11/03/2025 | — | Guggenheim | — | Downgrade | Buy → Neutral | |||
10/21/2025 | 3.87% | Morgan Stanley | $50 → $44 | Maintains | Overweight | |||
10/21/2025 | 6.23% | RBC Capital | $45 → $45 | Reiterates | Sector Perform → Sector Perform | |||
10/21/2025 | -29.18% | Wells Fargo | $36 → $30 | Maintains | Equal-Weight | |||
10/21/2025 | 13.31% | Leerink Partners | → $48 | Upgrade | Market Perform → Outperform | |||
09/17/2025 | 18.04% | Morgan Stanley | $46 → $50 | Maintains | Overweight | |||
09/17/2025 | 10.95% | Goldman Sachs | → $47 | Initiates | → Buy | |||
09/17/2025 | -5.57% | Barclays | → $40 | Initiates | → Equal-Weight | |||
08/12/2025 | 8.59% | HC Wainwright & Co. | $53 → $46 | Maintains | Buy | |||
07/30/2025 | -10.29% | UBS | $43 → $38 | Maintains | Neutral | |||
07/29/2025 | 15.68% | Truist Securities | $56 → $49 | Maintains | Buy | |||
07/29/2025 | 8.59% | Morgan Stanley | $48 → $46 | Maintains | Overweight | |||
07/29/2025 | 6.23% | RBC Capital | $50 → $45 | Maintains | Sector Perform | |||
07/29/2025 | 18.04% | JMP Securities | $50 → $50 | Reiterates | Market Outperform → Market Outperform | |||
07/29/2025 | 6.23% | Guggenheim | $45 → $45 | Reiterates | Buy → Buy | |||
07/29/2025 | -3.21% | Stifel | $38 → $41 | Maintains | Hold | |||
07/22/2025 | 13.31% | Morgan Stanley | $47 → $48 | Maintains | Overweight | |||
07/15/2025 | 32.2% | Truist Securities | $55 → $56 | Maintains | Buy | |||
07/11/2025 | 1.51% | UBS | $38 → $43 | Maintains | Neutral | |||
07/10/2025 | -5.57% | Barclays | $29 → $40 | Maintains | Equal-Weight | |||
06/30/2025 | 25.12% | HC Wainwright & Co. | $47 → $53 | Maintains | Buy | |||
06/24/2025 | 41.64% | Stephens & Co. | $29 → $60 | Upgrade | Equal-Weight → Overweight | |||
06/23/2025 | 29.84% | Truist Securities | $43 → $55 | Reiterates | Buy → Buy | |||
06/23/2025 | 18.04% | JMP Securities | $47 → $50 | Maintains | Market Outperform | |||
06/12/2025 | 10.95% | HC Wainwright & Co. | $40 → $47 | Maintains | Buy | |||
06/05/2025 | 8.59% | B of A Securities | $45 → $46 | Maintains | Neutral | |||
05/15/2025 | 32.2% | Citigroup | $45 → $56 | Maintains | Buy | |||
05/14/2025 | -10.29% | Stifel | $36 → $38 | Maintains | Hold | |||
05/14/2025 | -5.57% | RBC Capital | $40 → $40 | Reiterates | Outperform → Outperform | |||
05/14/2025 | 10.95% | Morgan Stanley | $40 → $47 | Maintains | Overweight | |||
04/17/2025 | -3.21% | JMP Securities | $41 → $41 | Reiterates | Market Outperform → Market Outperform | |||
03/27/2025 | -5.57% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
03/13/2025 | -5.57% | RBC Capital | $38 → $40 | Maintains | Outperform | |||
02/24/2025 | -15.01% | Wells Fargo | $36 → $36 | Downgrade | Overweight → Equal-Weight | |||
02/13/2025 | -31.54% | Barclays | $25 → $29 | Maintains | Equal-Weight | |||
02/13/2025 | -5.57% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
02/12/2025 | 6.23% | Citigroup | $38 → $45 | Maintains | Buy | |||
02/12/2025 | -0.85% | Guggenheim | $42 → $42 | Reiterates | Buy → Buy | |||
02/12/2025 | -31.54% | Stephens & Co. | $29 → $29 | Reiterates | Equal-Weight → Equal-Weight | |||
02/12/2025 | -15.01% | Stifel | $30 → $36 | Maintains | Hold | |||
02/12/2025 | -10.29% | Piper Sandler | $37 → $38 | Maintains | Overweight | |||
01/28/2025 | -19.74% | UBS | $30 → $34 | Maintains | Neutral | |||
01/27/2025 | -3.21% | JMP Securities | $41 → $41 | Maintains | Market Outperform | |||
01/27/2025 | 1.51% | Truist Securities | $42 → $43 | Maintains | Buy | |||
01/27/2025 | -31.54% | Stephens & Co. | $29 → $29 | Reiterates | Equal-Weight → Equal-Weight | |||
01/27/2025 | -5.57% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
01/27/2025 | -5.57% | Morgan Stanley | $30 → $40 | Upgrade | Equal-Weight → Overweight | |||
01/24/2025 | -22.1% | Oppenheimer | $41 → $33 | Downgrade | Outperform → Perform | |||
01/23/2025 | -3.21% | JMP Securities | $41 → $41 | Reiterates | Market Outperform → Market Outperform | |||
01/22/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
01/16/2025 | -3.21% | Oppenheimer | $38 → $41 | Maintains | Outperform | |||
01/15/2025 | -0.85% | Truist Securities | $38 → $42 | Maintains | Buy | |||
01/15/2025 | -3.21% | JMP Securities | $34 → $41 | Maintains | Market Outperform | |||
01/13/2025 | -12.65% | Piper Sandler | $36 → $37 | Maintains | Overweight | |||
01/10/2025 | -5.57% | HC Wainwright & Co. | $29 → $40 | Maintains | Buy | |||
01/07/2025 | -0.85% | Guggenheim | $33 → $42 | Maintains | Buy | |||
12/23/2024 | — | Brookline Capital | — | Initiates | → Buy | |||
12/20/2024 | -5.57% | BMO Capital | $36 → $40 | Downgrade | Outperform → Market Perform | |||
12/17/2024 | -7.93% | B of A Securities | $35 → $39 | Downgrade | Buy → Neutral | |||
10/30/2024 | -22.1% | Guggenheim | $32 → $33 | Maintains | Buy | |||
10/30/2024 | -31.54% | Stephens & Co. | $23 → $29 | Maintains | Equal-Weight | |||
10/30/2024 | -15.01% | Piper Sandler | $33 → $36 | Maintains | Overweight | |||
10/30/2024 | -19.74% | RBC Capital | $34 → $34 | Reiterates | Outperform → Outperform | |||
10/30/2024 | -10.29% | Truist Securities | $33 → $38 | Maintains | Buy | |||
10/30/2024 | -15.01% | Wells Fargo | $32 → $36 | Maintains | Overweight | |||
10/30/2024 | -15.01% | BMO Capital | $29 → $36 | Maintains | Outperform | |||
10/21/2024 | -19.74% | TD Cowen | $27 → $34 | Maintains | Buy | |||
10/16/2024 | -29.18% | Stifel | $26 → $30 | Maintains | Hold | |||
10/16/2024 | -19.74% | RBC Capital | $30 → $34 | Maintains | Outperform | |||
10/16/2024 | -19.74% | JMP Securities | $29 → $34 | Maintains | Market Outperform | |||
10/15/2024 | -29.18% | Morgan Stanley | $28 → $30 | Maintains | Equal-Weight | |||
10/15/2024 | -24.46% | B of A Securities | $30 → $32 | Maintains | Buy | |||
10/11/2024 | -31.54% | JMP Securities | $29 → $29 | Reiterates | Market Outperform → Market Outperform | |||
10/11/2024 | -33.9% | Morgan Stanley | $26 → $28 | Maintains | Equal-Weight | |||
10/04/2024 | -29.18% | RBC Capital | $27 → $30 | Maintains | Outperform | |||
09/26/2024 | -36.26% | RBC Capital | $27 → $27 | Reiterates | Outperform → Outperform | |||
09/20/2024 | -31.54% | JMP Securities | $29 → $29 | Reiterates | Market Outperform → Market Outperform | |||
09/19/2024 | -29.18% | UBS | → $30 | Initiates | → Neutral | |||
09/18/2024 | -31.54% | HC Wainwright & Co. | $29 → $29 | Reiterates | Buy → Buy | |||
08/08/2024 | -22.1% | Truist Securities | $32 → $33 | Reiterates | Buy → Buy | |||
08/07/2024 | -31.54% | JMP Securities | $27 → $29 | Maintains | Market Outperform | |||
08/07/2024 | -36.26% | RBC Capital | $27 → $27 | Reiterates | Outperform → Outperform | |||
07/30/2024 | -31.54% | Oppenheimer | $29 → $29 | Maintains | Outperform | |||
05/14/2024 | -45.7% | Stephens & Co. | → $23 | Initiates | → Equal-Weight | |||
05/03/2024 | -33.9% | HC Wainwright & Co. | $28 → $28 | Reiterates | Buy → Buy | |||
05/01/2024 | -36.26% | TD Cowen | $25 → $27 | Maintains | Buy | |||
04/11/2024 | -40.98% | Barclays | $25 → $25 | Downgrade | Overweight → Equal-Weight | |||
04/10/2024 | -36.26% | JMP Securities | $27 → $27 | Reiterates | Market Outperform → Market Outperform | |||
02/07/2024 | -33.9% | RBC Capital | $26 → $28 | Maintains | Outperform | |||
02/02/2024 | -40.98% | Stifel | $23 → $25 | Maintains | Hold | |||
01/30/2024 | -40.98% | Barclays | $24 → $25 | Maintains | Overweight | |||
12/19/2023 | -36.26% | BTIG | → $27 | Initiates | → Buy | |||
12/15/2023 | -26.82% | Citigroup | → $31 | Initiates | → Buy | |||
12/14/2023 | -36.26% | JMP Securities | $27 → $27 | Reiterates | Market Outperform → Market Outperform | |||
12/13/2023 | -38.62% | RBC Capital | $26 → $26 | Reiterates | Outperform → Outperform |
FAQ
Quel est le cours indicatif de l'action Exelixis (EXEL) ?
Le dernier objectif de prix pour Exelixis (NASDAQ:EXEL) a été rapporté par UBS le novembre 6, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $40.00 s'attendant à ce que EXEL se fall dans les 12 prochains mois (un possible changement de -5.57% downside). 64 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Exelixis (EXEL) ?
La dernière note d'analyste pour Exelixis (NASDAQ:EXEL) a été fournie par UBS, et Exelixis maintenu leur note neutral.
Quand a eu lieu la dernière mise à niveau pour Exelixis (EXEL) ?
La dernière amélioration pour Exelixis Inc a eu lieu le octobre 21, 2025 lorsque Leerink Partners a augmenté leur objectif de prix à $48. Leerink Partners avait précédemment a market perform pour Exelixis Inc.
Quand a eu lieu la dernière dégradation pour Exelixis (EXEL) ?
La dernière réduction pour Exelixis Inc a eu lieu le novembre 3, 2025 lorsque Guggenheim a changé leur objectif de prix de N/A à N/A pour Exelixis Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Exelixis (EXEL) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Exelixis, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Exelixis a été déposée le novembre 6, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 6, 2026.
La note d'analyste pour Exelixis (EXEL) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Exelixis (EXEL) était un maintenu avec un objectif de prix de $35.00 à $40.00. Le prix actuel de Exelixis (EXEL) est de $42.36, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.